Latest Articlesddd

Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine

February 8, 2024 0

Madrigal Pharmaceuticals Publication in the New England Journal of Medicine Resmetirom is the first investigational medicine …

Published in Nature Communications: MiNK Therapeutics’ AgenT-797 Demonstrates Promising Results in the Treatment of Severe Acute Respiratory Distress

February 6, 2024 0

MiNK Therapeutics in the NEWS  Today, February 6, 2024, MiNK Therapeutics (INKT) announced the publication of the …

Vera Therapeutics to Participate in Guggenheim Healthcare Talks 6th Annual Biotechnology Conference and More

February 2, 2024 0

Vera Therapeutics to Participate in Guggenheim Healthcare Talks February 2, 2024, Vera Therapeutics, Inc. (VERA) announced …

Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in the New England Journal of Medicine

February 1, 2024 0

Intellia Therapeutics in the NEWS Yesterday, January 31, Intellia Therapeutics (NTLA) announced that the results from …

Abbott Laboratories Launches a New PROTALITY™ Brand to Maintain the Muscle Mass of Adults Pursuing Weight Loss by Various Means

February 1, 2024 0

Abbott Laboratories New PROTALITY™ for Maintaining Muscle Mass During Weight Loss Abbott Laboratories (ABT) announced the …

Vertex Pharmaceuticals Announced Positive Results from its Non-Opioid Product VX-548

January 30, 2024 0

Vertex Pharmaceuticals Positive Results for VX-548 Today, Vertex Pharmaceuticals (VRTX) announced positive results from its Phase …

Apellis Announces Negative CHMP Opinion on Pegcetacoplan for GA in the EU and Its Plans to Seek Re-Examination of Application

January 27, 2024 0

Apellis Pharmaceuticals Negative CHMP Opinion Apellis Pharmaceuticals (APLS) announced that the Committee for Medicinal Products for …

Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy

January 25, 2024 0

Vera Therapeutics Positive Data Announcement Vera Therapeutics (VERA) announced positive 72-week data from the open label …

Eli Lilly Gene Therapy Restores Patient Hearing

January 24, 2024 0

Akous Inc to Present at the Association for Research in Otolaryngology Akouos, Inc. - a wholly …

Sanofi to Acquire Inhibrx, Inc.

January 23, 2024 0

Sanofi to Acquire Inhibrx Inc Paris, January 23, 2024, Sanofi (SNY) and Inhibrx, Inc. (INBX) entered …

Ionis Pharmaceuticals: Positive Results from Phase 3 OASIS-HAE Study of Investigational Donidalorsen for Hereditary Angioedema

January 22, 2024 0

Ionis Pharmaceuticals in the NEWS Ionis Pharmaceuticals (IONS) today announced positive topline results for the Phase …

Lexaria Bioscience Unveils Extensive Planned 2024 GLP-1 Study Program

January 16, 2024 0

Lexaria Bioscience Extensive Program Designed to Support Commercial Discussions. January 16, 2024, Lexaria Bioscience (LEXX) announced …

OKYO Pharma Limited: Another Ophthalmology Firm with Promising Eye Treatment

January 11, 2024 0

Improving eyesight is speeding towards treating devastating eye diseases from the Retina in the back of …

Vertex Pharmaceuticals Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

January 9, 2024 0

Vertex Pharmaceuticals Updates Vertex Pharmaceuticals (VRTX) announced multiple program updates ahead of the upcoming investor meetings …

Cognition Therapeutics CEO Issues Letter to Shareholders

January 4, 2024 0

Cognition Therapeutics CEO Letter to Shareholders Cognition Therapeutics (CGTX) today announced that CEO Lisa Ricciardi has …

CymaBay Therapeutics: New Published Data Demonstrates Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement

January 3, 2024 0

CymaBay Therapeutics in the NEWS CymaBay Therapeutics (CBAY) today announced the first published findings demonstrating the …

Yes, Compugen’s Stock is Soaring, But Why?

January 2, 2024 0

Compugen's Soaring Stock Many recent events  led to Compugen's (CGEN) soaring stock after a huge decline …

Cytokinetics Announces Positive Results from a Pivotal Phase 3 Clinical Trial of Aficamten

December 29, 2023 0

Cytokinetics We recently became enthusiastic about Cytokinetics’ (CYTK) current clinical trial results. A few days ago, …

Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label

December 28, 2023 0

Sarepta Therapeutics in the NEWS On 12, 22, 2023, Sarepta Therapeutics (SRPT) - a precision genetic …

Why Arcturus Therapeutics Holdings’ Pipeline Products are Promising

December 27, 2023 0

The information is the first of a few biotech Companies that we believe are promising in …